Amyotropyc Lateral Sclerosis and Endogenous -Esogenous Toxicological Movens: New model to verify other Pharmacological Strategies
Open Access
- 5 October 2018
- journal article
- Published by Heighten Science Publications Corporation
- Vol. 2 (1), 029-048
- https://doi.org/10.29328/journal.apcr.1001009
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Nanoparticles as potential clinical therapeutic agents in Alzheimer’s disease: focus on selenium nanoparticlesExpert Review of Clinical Pharmacology, 2017
- Selenium and zinc protect brain mitochondrial antioxidants and electron transport chain enzymes following postnatal protein malnutritionLife Sciences, 2016
- A comprehensive review of amyotrophic lateral sclerosisSurgical Neurology International, 2015
- Mitochondrial dysfunction in amyotrophic lateral sclerosis – a valid pharmacological target?British Journal of Pharmacology, 2014
- Strategies for drug delivery to the central nervous system by systemic routeDrug Delivery, 2014
- Concurrent blockade of free radical and microsomal prostaglandin E synthase‐1‐mediated PGE2 production improves safety and efficacy in a mouse model of amyotrophic lateral sclerosisJournal of Neurochemistry, 2012
- The ALS/PDC syndrome of Guam: Potential biomarkers for an enigmatic disorderProgress in Neurobiology, 2011
- ALS motor phenotype heterogeneity, focality, and spreadNeurology, 2009
- Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative diseaseBMC Neuroscience, 2008
- Enhanced Fos expression in rat lumbar spinal cord cultured with cerebrospinal fluid from patients with amyotrophic lateral sclerosis.Neurological Research, 1999